IntuitionLabs

INTUITIONLABS / RESEARCH & PRACTICAL GUIDANCE

Veeva Vault 26R2 Preview: Platform & Module Updates

> Build practical AI for pharma and biotech with IntuitionLabs. We help life-science teams turn complex information and workflows into useful software, governed knowledge systems and AI tools.

Published by IntuitionLabs · 2026-04-26 · veeva vault 26r2 · release preview · document management · quality management system · pharmacovigilance · ctms · life sciences software

Original article: https://intuitionlabs.ai/articles/veeva-vault-26r2-release-preview



In this article

1. Executive Summary
2. Introduction and Background
3. Vault Platform and Document Management Enhancements
4. Quality Management (Vault Quality) Enhancements
5. Regulatory Information Management (RIM) Enhancements
6. Clinical Trial Management and eTMF Enhancements
7. Safety (Pharmacovigilance) Enhancements
8. Developer Ecosystem and AI Integration
9. Data Integration and Analytics
10. Case Studies and Real-World Examples
11. Discussion: Implications and Future Directions
12. Conclusion

Executive Summary

The **Veeva Vault 26R2** release (generally released July 31 and August 7, 2026) includes targeted enhancements across the Vault platform to advance life-sciences regulatory, quality, clinical, and safety workflows. According to Veeva's own release announcements, major investments are focused on *user experience and automation*: e.g. an overhauled **Document Viewer** (streamlined toolbar, side-by-side view, AI-powered compare) and a responsive UI that adapts to different screen sizes (rn.veevavault.help). These platform upgrades align with industry dynamics. The global regulatory information management market is projected to grow from **USD 2.7B in 2026 to $7.6B by 2036 (11% CAGR)** (www.futuremarketinsights.com), and the pharmacovigilance (drug safety) market is forecast at **$10.5B in 2026, surging to $31.6B by 2034** (14.7% CAGR) (www.fortunebusinessinsights.com). Similarly, investment in cloud-based quality systems is accelerating: life-sciences companies "continue to invest in cloud-based, AI-enabled electronic quality management systems" (www.firstanalysis.com).

This report provides an in-depth review of Vault 26R2. We first review Vault's scope and release process, then analyze the platform and module enhancements. Each section draws on official Veeva documentation, industry reports, and practical case studies. We examine updates in the Vault **platform and document management**, **quality (QMS)**, **regulatory (RIM)**, **clinical/CTMS**, and **safety (PV)** modules. Detailed tables summarize key new features and relevant market data. Finally, we discuss the implications of Vault 26R2 against broader life-science IT trends (cloud adoption, AI integration, global regulatory compliance) and highlight real-world examples of Vault implementations. This article draws on Veeva's 26R2 announcements and release notes.

Introduction and Background

Veeva Vault is a flagship cloud platform for regulated content and data management in life sciences. Vault is built as a multi-tenant SaaS system that unifies documents and data across R&D, clinical, regulatory, safety, and commercial functions. Veeva Vault applications are used by many pharmaceutical and biotech firms for clinical documentation, regulatory submissions, and quality management, and Vault Quality (QualityDocs/QMS) is among them. Customer-reported efficiency gains are discussed in the case studies below.

Vault's success stems from addressing the regulated environment: it provides features such as audit trails and electronic signatures that customers can use to support their own compliance programs, including controls under 21 CFR Part 11 and GxP expectations. Whether a given deployment meets regulatory requirements depends on the customer's configuration, validation, and procedures.

Veeva follows a rapid release cadence: Vault has three general releases each year, roughly every four months, with limited releases in between. The **26R1** release occurred in April 2026, and **26R2** was released to production on July 31 and August 7, 2026 (pre-release July 13, 2026). The *Latest Announcements* page on Veeva's release site described the following 26R2 platform changes: an improved document viewer with AI integration, a more responsive UI, and greater flexibility in document inbox processing (rn.veevavault.help). We base our analysis on these official announcements and the 26R2 release notes, supplemented by trends in prior releases and industry context.

> **Table 1.** *Projected Market Growth for Key Vault Domains (2026–2030s)*. Vault's target modules align with fast-growing life-science software markets. Sources: Mordor Intelligence (www.mordorintelligence.com), FutureMarketInsights (www.futuremarketinsights.com), Grand View Research (www.grandviewresearch.com), Fortune Business Insights (www.fortunebusinessinsights.com).

Domain	Market Size (base year)	Forecast (future)	CAGR	Source
Pharmaceutical Management Software	$3.67 B (2026)	$7.12 B (2032)	~11.67% (2027–2032)	(www.mordorintelligence.com) (Mordor)
Regulatory Info Management	$2.7 B (2026)	$7.6 B (2036)	~11%	(www.futuremarketinsights.com) (FMI)
CTMS (Clinical Trial Mgmt.)	$2.7 B (2026)	$7.4 B (2033)	~15.6% (2026–2033)	(www.grandviewresearch.com) (GVR)
Pharmacovigilance (PV)	$10.54 B (2026)	$31.56 B (2034)	~14.7%	(www.fortunebusinessinsights.com) (FBI)

Each of these segments is expanding rapidly as life-sciences firms digitize their processes. This market context underscores the strategic importance of Vault's continual enhancements.

Vault Platform and Document Management Enhancements

Veeva Vault is first and foremost a content management platform. The **26R2** release includes significant UI/UX upgrades that affect Vault customers. Chief among these is the **new Document Viewer**. According to Veeva, the 26R2 document viewer has a *streamlined toolbar*, enhanced full-screen mode, and smarter search within a document set (rn.veevavault.help).Users can also view documents side-by-side more easily, and even perform a one-click version compare with an AI-generated summary (for customers with Veeva AI) (rn.veevavault.help). These improvements aim to reduce the steps needed to analyze documents and make version comparisons more intuitive.

In parallel, 26R2 introduces a **responsive design** across the Vault UI. Veeva has stated that the layout will now adjust to different screen sizes, minimizing unnecessary whitespace and scrolling (rn.veevavault.help). In practice, this means users working on laptops, tablets, or split screens should experience a cleaner, more efficient layout. Veeva expects this to improve multi-tasking and make the interface more modern and accessible. These front-end enhancements reflect a broader trend: regulated life-science teams increasingly expect consumer-grade usability, and vendors like Veeva are responding by modernizing their UIs (rn.veevavault.help).

Another 26R2 improvement affects the **Document Inbox** workflow. Veeva now allows users to change a document's type (classification) even if they have not completed all data fields. In older releases, a document in the Inbox could be "Unclassified" until all metadata was entered, preventing earlier routing. The 26R2 release notes state that the label "Unclassified" is renamed to "Incomplete", and users can edit the type without finishing all fields (rn.veevavault.help). This increases flexibility in intake workflows – for example, a document can be tagged and partially processed without delays. (However, all required fields must still be filled before final completion.) This subtle change should streamline document review processes with minimal disruption to existing business rules.

Veeva is also continuing to bolster its development ecosystem. (The **Vault Developer Portal**, introduced in the 26R1 cycle, is where the 26R2 notes point readers for developer features.) The portal (available at *veevavault.dev*) consolidates technical documentation for Vault's REST APIs, Java SDK, VQL, and MDL in one searchable site (rn.veevavault.help). Developers gain clearer guidance on integration and customization. Additionally, 26R2 adds Layout Profile support to **Action Triggers**: admins can evaluate Layout Profiles in a condition and use Update Records (rn.veevavault.help). Taken together, platform improvements in 26R2 – from the front-end viewer to developer tools – reflect Veeva's shift toward a more dynamic, AI-augmented Vault. These changes benefit all modules by making Vault easier to use and extend.

Quality Management (Vault Quality) Enhancements

Vault Quality (QualityDocs/QMS) supports quality processes like change control, deviations, CAPA, and supplier management. The life-science market for QMS is booming: analysts project the broader pharmaceutical management software market (of which quality management is one segment) to grow from $3.67B in 2026 to $7.12B by 2032 (a CAGR of 11.67% over 2027–2032) (www.mordorintelligence.com). A recent report notes that evolving regulations (data integrity, risk-based QA) and the rise of biologics are driving broad **digital QMS adoption** in pharma (www.firstanalysis.com). Vendors that embed auditing, e-signatures, and transparency are in high demand, as companies replace aging legacy systems.

Veeva's QMS customers already report tangible benefits. For example, Clarkston Consulting documents a major transformation for a leading biopharmaceutical company: that client migrated from TrackWise and Agile to a unified Vault Quality system in a three-year project, *"impacting thousands of users across over a dozen offices globally"* (clarkstonconsulting.com). Another case: Merck KGaA streamlined its global quality processes for **20,000 users** by replacing legacy solutions with Vault. In Veeva's customer story on its phased Vault QMS rollout, Merck reports that it has **standardized processes across business units, significantly reduced process steps**, and delivered a *"simplified site experience"* (www.veeva.com). Meanwhile, Atrium Innovations, a vitamins, minerals and supplements company, reports approximately **50% shorter cycle times** from complaint logging to resolution across quality/regulatory teams after deploying Vault Quality (www.veeva.com). These examples illustrate how Vault QMS harmonizes procedures and data, improving visibility and compliance.

26R2 Quality Updates: The 26R2 release notes document changes to the Quality-RIM Connection, summarized below.

In summary, the 26R2 release notes show Vault Quality continuing to integrate with RIM: any document or document version created directly in its steady state now triggers the Quality-RIM Document Integration. (rn.veevavault.help) When combined with market pressures (growing QMS spend, regulatory convergence), these enhancements should help customers continue the transition from paper and legacy systems to a modern, cloud-based QMS (www.firstanalysis.com) (clarkstonconsulting.com).

Regulatory Information Management (RIM) Enhancements

The **Vault RIM** module (including RegulatoryOne) manages submissions planning, eCTD publishing, registrations, and product dossiers. With global regulations constantly evolving, regulatory teams are increasingly reliant on central systems. The global RIM software market is projected at **$2.7B in 2026**, rising to **$7.6B by 2036** (www.futuremarketinsights.com), a roughly 11% CAGR. Leading RIM vendors (like Veeva and ArisGlobal) dominate this fast-growing segment. This growth is driven by needs for compliance automation, regulatory change management, and end-to-end lifecycle tracking.

Vault's existing RIM capabilities are robust: it supports multi-country submission planning (IND, NDA, MAA, etc.), dossier assembly, and regulator correspondence. In 26R2, RIM Vaults using the RIM-Clinical Operations Connection will record connection transactions in the Vault Platform's Connection Stats object. (rn.veevavault.help)

A practical illustration comes from an organization adopting Vault RIM. Astrix Inc. reports one global pharma migrating from SharePoint, spreadsheets, and region-specific tracking tools to a centralized Veeva RIM platform (www.astrixinc.com). That project involved redefining global processes for submission planning, authoring, publishing, and archiving all through Vault RIM (www.astrixinc.com). The case study describes the organization's submission planning, authoring, publishing, and archiving processes in the context of its Vault RIM implementation (www.astrixinc.com). In 26R2, the Safety-RIM Connection also adds granular substance strength tracking at the Product Variant level (rn.veevavault.help), and the document viewer and inbox changes apply to RIM users authoring and reviewing submission documents.

Clinical Trial Management and eTMF Enhancements

Vault also offers **clinical operations** modules, including an Electronic Trial Master File (eTMF) and Clinical Trial Management System (CTMS). These handle trial documentation (protocols, eCRFs, site licenses, etc.) and trial processes (planning, site tracking). The CTMS market is substantial: projected to grow from about $2.7B in 2026 to $7.4B by 2033 (CAGR ~15.6% over 2026–2033) (www.grandviewresearch.com). Growth is propelled by increased trial complexity, decentralized trials, and sponsor-CRO collaborations. Life-sciences firms demand agile, cloud-based platforms for trial oversight.

Veeva's 26R2 release notes describe a new Clinical Operations-Vault CRM Connection that bridges the gap between clinical study and commercial teams (rn.veevavault.help). The improved generic document viewer and inbox also benefit clinical users who handle protocol amendments and site documents.

To illustrate the value of Vault in clinical, consider that regulators and auditors now scrutinize trial master files closely. In the future, we anticipate Vault to integrate even more with electronic data capture (EDC) and patient data, possibly incorporating AI agents to flag missing documents or guide compliance.

Safety (Pharmacovigilance) Enhancements

Vault Safety handles global adverse event report intake, case processing, and submission management. This is a rapidly expanding area: the global pharmacovigilance market (services + software) is projected to grow from about **$10.5B in 2026 to $31.6B in 2034** (www.fortunebusinessinsights.com) (nearly 15% annual growth). Drivers include higher post-market surveillance demands and regulatory scrutiny. Modern safety systems are expected to support global case exchange standards and automation of ICSR submissions.

For instance, Haleon (GSK Consumer Healthcare) reduced its safety systems from 11 to 4 by switching to Vault Safety (www.veeva.com). Haleon reported *"improved data quality and process efficiency"* (www.veeva.com).

The 26R2 release notes describe updates to Vault Safety's connections: the Safety-RIM Connection now supports granular substance strength tracking at the Product Variant level, and the Safety-EDC Connection adds optimized data exchange to improve the efficiency of safety intake (rn.veevavault.help). Moreover, the user interface and document improvements in 26R2 (e.g. viewer, inbox) will help safety staff review narratives and attached documents faster, possibly with AI summarization in the cloud viewer.

In short, the Vault 26R2 safety-related updates are intended to support pharmacovigilance teams' efficiency. By unifying data on a cloud platform, Vault can support customers' own safety-reporting compliance programs while reducing manual effort. Haleon says it expects the capabilities of Vault Safety to help it streamline, gain efficiency and improve data quality, and to *"free up resources so that we can really focus on what matters most"* (www.veeva.com).

Developer Ecosystem and AI Integration

Modern Vault releases increasingly emphasize developer tooling and artificial intelligence – trends that continue in 26R2. The new **Vault Developer Portal** (piloted in 26R1) centralizes documentation for Vault's REST APIs, Java SDK, VQL query language, and metadata modeling (MDL) (rn.veevavault.help). In practice, this makes it easier for organizations to build integrations with Vault or develop custom workflows. As Vault embraces more platform-level logic (Action Triggers, VQL-coded rules), such developer support is critical.

Generative AI is another key theme. Veeva has begun bundling "Veeva AI Agents" into its portfolio – prebuilt assistant bots that leverage large language models. The platform documentation confirms that Vault AI allows administrators to configure *custom agents* with secure access to Vault data (platform.veevavault.help). The 26R2 release notes document a Query Agent, a Platform agent that allows users to receive answers to data-related questions in plain language, and a Document Version Compare Agent that helps users quickly grasp key changes between two document versions at a high level (rn.veevavault.help). The "AI Summary" mention in the document compare feature (rn.veevavault.help) hints that Vault is already surfacing GPT-like capabilities to end users.

As a concrete reference, Vault's platform documentation explicitly describes the AI architecture: Platform Vault AI allows admins to configure custom agents with direct and secure access to Vault object and document data (platform.veevavault.help). This capability bridges natural language querying and compliance – e.g. a user might ask, "Show me all open CAPAs tagged to FDA 21CFR11 issues," and receive contextual answers. With 26R2 delivery of an AI-powered viewer and the official agents, Vault is aligning with the industry's shift toward intelligent automation and semantic insight. In turn, life-sciences CIOs will need to adapt validation and data governance for these AI features, but the potential productivity gains are significant.

Data Integration and Analytics

Beyond individual modules, Vault's vision has long included connected data and analytics across the enterprise. Veeva's architecture (the *Vault Builder* metadata layer) encourages that documents and objects from different modules interoperate, through defined connections (e.g. linking clinical studies to regulatory submissions, or quality change items to safety cases). The 26R2 enhancements continue this integration

paradigm. For instance, the 26R2 release notes describe optimized data exchange in the Safety-EDC Connection to streamline the exchange of clinical trial data and improve the efficiency of safety intake (rn.veevavault.help).

From an analytics standpoint, Modern life-sciences operations rely heavily on metrics (e.g. number of safety cases filed, average deviation closure times, regulatory review milestones), so connection and usage tracking matters for oversight.

In this context, Vault 26R2 should facilitate better oversight. The new document viewer's quick-search and AI summary may help quality reviewers catch trends in audit documents. The Inbox classification flexibility reduces bottlenecks, smoothing data flow into analytics dashboards. And as custom objects and triggers grow, Vault's full-featured APIs will ensure that downstream analytics (cloud BI or third-party) receive cleaner, more complete data. Ultimately, the combination of enhanced platform features and open data pipelines positions Vault 26R2 as a richer enterprise data hub.

Case Studies and Real-World Examples

Pharma Quality Transformation: Several customer case studies, mostly self-reported, describe how organizations use Vault to pursue operational efficiency. Merck KGaA (Darmstadt, Germany) undertook a *"cross-functional business transformation"* to unify its legacy quality systems into Vault (www.veeva.com). Merck reports, in Veeva's customer story, reduced process steps and redundancies across quality operations (www.veeva.com). Similarly, Atrium Innovations, a vitamins, minerals and supplements company, reports an approximately **50% reduction in cycle time** from complaint to action or closure by giving quality and regulatory teams real-time visibility into complaint records via Vault (www.veeva.com). These examples show that Vault's integrated data model can eliminate redundant documentation and speed decision-making (a crucial advantage as pharma companies expend more on compliance).

Regulatory Excellence: A global top-10 pharma implemented Veeva RIM to centralize processes previously managed through Excel trackers and SharePoint sites. Before Vault, regional offices used a range of tools and processes (www.astrixinc.com). By migrating to Vault RegulatoryOne, the company harmonized submission planning, authoring, publishing, and archiving across the organization (www.astrixinc.com). This mirrors a broader trend: regulators and inspectors demand consistency, so having a single platform like Vault RIM can help centralize and standardize submission processes, supporting a company's own compliance program.

Consolidating Safety Operations: Haleon (the global consumer health spinout from GSK) provides a vivid case. Haleon reduced its global safety applications from **11 disparate systems down to 4** by adopting Vault Safety (www.veeva.com). In Veeva's own customer story, the switch is reported to have *"led to improved data quality and process efficiency"* (www.veeva.com).

Quality Process Harmonization: Clarkston Consulting reports that their client, a leading biopharmaceutical company, unified its QMS on Vault. That engagement transitioned QMS processes from TrackWise and Agile to a **multi-site Vault Quality environment** servicing thousands of users (clarkstonconsulting.com). Clarkston describes the engagement as aimed at global harmonization of the client's quality systems into a single Quality

Ecosystem. This case underscores a key benefit: Vault's continuous delivery model means that best practices roll out to all users simultaneously. In effect, a feature added in 26R2, such as Layout Profile support in Action Triggers, becomes available across the enterprise.

These case studies demonstrate that Vault's modular apps (Quality, RIM, Safety) all contribute to an organization-wide digital transformation. The features in 26R2 are continuations of an ongoing shift toward a unified, cloud-native platform. In every example, efficiency gains and compliance improvements were closely tied to Vault's ability to integrate data and automate processes. Vault 26R2 continues in this direction; the benefit to any given customer depends on how it is adopted and configured.

Discussion: Implications and Future Directions

The Vault 26R2 release, when placed in context, suggests several broader insights for the life-sciences industry. First, **usability and integration continue to be top priorities**. The document viewer and UI enhancements will reduce friction in day-to-day work, which is critical given the complexity of document workflows. Simplicity (e.g. clicking, drag-and-drop, smart defaults) will free users to focus on compliance and analysis rather than on fiddling with the system. This matches the industry shift: a recent analysis observes that QMS and other regulated systems are no longer seen merely as compliance costs, but as strategic enablers of efficiency (www.firstanalysis.com).

Second, the emphasis on **AI and automation** indicates that Vault is evolving from a passive repository to an *active assistant*. The integration of AI agents and smart features (like summary compare) is timely: many life-science companies are now exploring AI to manage exploding data volumes (www.striped-giraffe.com) intuitionlabs.ai. Veeva's approach (licensed AI agents, configurable within Vault) suggests a measured strategy that maintains regulatory controls. Administrators can monitor token usage and agent outcomes (platform.veevavault.help).

Third, Vault is enabling **enterprise data unity**. The announced features for 26R2, together with existing module linkages, mean that organizations adopting them can reduce data silos. As an example, Vault's Safety and RIM teams may begin to share product information automatically, or clinical trial metadata might flow into regulatory planning. Such connectivity is crucial given survey evidence that **74% of healthcare/life-sciences organizations are accelerating cloud and interoperability projects** in the next few years (www.accessnewswire.com). Vault sits at the center of this cloud strategy. Its role is similar to that of modern ERP: coordinating data across quality, regulatory, and development.

Looking forward, several emerging trends may shape future Vault releases (beyond 26R2). The proliferation of AI agents hints that Veeva might incorporate new LLM-driven analytics (e.g. automated audit readiness checks, risk prediction). There is also pressure for **mobile accessibility** – while Vault has had some mobile apps (e.g. audit checklists), we expect continued investment so that inspectors, field reps, and patients can interact with Vault from anywhere. Another trend is **blockchain** or distributed ledger for audit trails; while Vault

already has versioning, future versions could integrate blockchain for even stronger provenance (though no official word yet). In addition, the move toward **patient-centric data** (real-world evidence) could lead to Vault integrations with patient apps or wearable data, as regulators demand post-market data reporting.

Finally, the implications for **compliance** are notable. Regular cloud releases can reduce the need for large upgrade projects, but regulatory compliance remains the customer's responsibility and depends on its configuration, validation, and procedures.

Conclusion

The 26R2 release materials indicate that Veeva is doubling down on the two forces reshaping life-science IT: user-centric cloud design and smart automation. The improvements to Vault's platform (Document Viewer, responsive UI, smarter inbox) will make the day-to-day experience more productive. At the same time, Vault continues to deepen its application-specific capabilities in Quality, Regulatory, Clinical, and Safety. The official 26R2 release notes, not this article's expectations, are the authoritative list of module-level features for QMS, RIM, and PV. We see Vault 26R2 as building on the success of prior releases, delivering incremental but meaningful enhancements that drive process efficiency and data integration.

For life-science organizations, adopting Vault 26R2 should reinforce centralized control over quality and compliance processes, while also allowing more adaptive workflows. The release comes at a time when regulatory expectations and competition demand faster development timelines. Vault 26R2's focus on seamless workflows (across modules) and intelligent assistance plays directly to these needs. In summary, Vault 26R2 is a vital step in the industry's ongoing digital transformation – in our view, and in a period of growing investment in cloud-based quality systems and a growing pharmacovigilance market (www.firstanalysis.com) (www.fortunebusinessinsights.com).

References: Key references include official Veeva release notes (rn.veevavault.help), industry market reports (www.mordorintelligence.com) (www.futuremarketinsights.com) (www.grandviewresearch.com) (www.fortunebusinessinsights.com), analyst publications (www.firstanalysis.com), and case studies from industry practitioners (clarkstonconsulting.com) (www.veeva.com) (www.astrixinc.com) (www.veeva.com). These provide the empirical foundation for this 26R2 release review.

Source links

Links cited in this article, in order of first appearance. Full addresses are provided for readers using extracted text.

1. https://rn.veevavault.help/en/gr/announcements
2. https://www.futuremarketinsights.com/reports/regulatory-information-management-market
3. https://www.fortunebusinessinsights.com/pharmacovigilance-pv-market-102746
4. https://www.firstanalysis.com/research/pharma-it-nov-2025
5. https://www.mordorintelligence.com/industry-reports/pharmaceutical-management-software-market
6. https://www.grandviewresearch.com/industry-analysis/clinical-trial-management-system-ctms-market
7. https://rn.veevavault.help/en/gr/whats-new-in-26r2

8. https://clarkstonconsulting.com/insights/implementing-a-global-veeva-vault-qms
9. https://www.veeva.com/customer-stories/merck-kgaa-driving-quality-transformation-across-the-enterprise
10. https://www.veeva.com/customer-stories/atrium-innovations-achieves-real-time-visibility-across-global-quality-operations
11. https://www.astrixinc.com/case/global-pharmaceutical-company-successfully-implements-a-veeva-rim-solution
12. https://www.veeva.com/customer-stories/connecting-safety-quality-and-regulatory-systems-for-operational-efficiency
13. https://platform.veevavault.help/en/gr/1030840
14. https://www.striped-giraffe.com/de/blog/zentrale-treiber-der-cloud-adoption-in-pharma-und-life-sciences
15. https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/black-book-global-healthcare-cloud-adoption-surges-toward-enterprise-1059906

THE PUBLISHER

About IntuitionLabs

IntuitionLabs is an AI consulting, custom software development and data engineering firm serving pharmaceutical, biotechnology, medical-device and other life-science organizations. We work with clinical, regulatory, medical-affairs, commercial, quality and IT teams to connect technology decisions with the work people need to accomplish.

AI consulting and adoption

Our AI enablement services cover readiness assessments, use-case selection, governance and policies, team workshops, adoption measurement and ongoing advisory support. We help organizations structure the information layer behind AI: source material, context, permissions and maintained knowledge that make generated answers useful and reviewable. Private LLM inference and hosted AI options support teams evaluating how to operate AI with appropriate control over their data and infrastructure.

Software, data and life-science workflows

IntuitionLabs develops custom software for pharma and biotech, integrates enterprise systems, and builds data engineering and business intelligence solutions. Areas of focus include AI agents, regulatory research, medical writing, medical affairs, CMC information, competitive intelligence and clinical-document workflows. Our eTMF intelligence work includes cross-system reconciliation and inspection-readiness support.

Enterprise platforms and regulated delivery

We provide Veeva services, application support, managed services, integrations and custom applications, alongside enterprise content work involving platforms such as Egnyte. For regulated workflows, our services include GxP enablement, computer-system validation and software development addressing 21 CFR Part 11 requirements. The applicable controls, validation responsibilities and acceptance criteria are defined for each engagement.

Work with IntuitionLabs

Explore AI enablement, pharma and biotech software development, data engineering and BI, and Veeva services. Contact IntuitionLabs to discuss your workflow, information sources and implementation needs.

IntuitionLabs publishes educational research to help life-science teams make informed technology decisions. Coverage of a product or organization does not imply a client relationship, endorsement or partnership.

Website: https://intuitionlabs.ai

This article is educational. Verify consequential medical, legal, financial, regulatory and technical decisions with appropriate professionals and the cited primary sources. Company services are described separately from the article's research findings.